Citicoline, graded by the evidence.

A closer reading

Why this site exists

Most citicoline pages on the internet are written by companies that sell citicoline, or by people paid by those companies. The result is predictable: small positive trials get headlines, and large negative trials get a sentence or nothing at all. A reader trying to make a real decision is left with marketing dressed up as medicine.

This site takes the opposite approach. Every claim on Citicoline.co is tied to a specific study or review, and every claim is graded by the strength of the evidence behind it. A large, well-run trial that found no benefit is reported as finding no benefit, in the same size type as the trials that found something. That is a low bar, but it is one most citicoline content does not clear.

The author of record is Dr. Alexander Tabibi, MD, trained at USC Keck in internal medicine. You can read more on the about page and the team page. The site does not sell its own product, and evidence pages carry no affiliate links. Where product suggestions exist at all, they live only on the choosing-a-supplement pages.

What citicoline is, in plain terms

Citicoline is a compound your body uses on the way to building cell membranes. It also goes by the name CDP-choline. These are two names for the same molecule, not two different supplements, and the CDP-choline naming page walks through why both names appear on labels and in studies. Cognizin is a branded form of that same compound, not a different or stronger molecule.

Laboratory research suggests citicoline supports the synthesis of membrane phospholipids, which is the plausible reason it was ever studied for brain conditions. It is important to be honest about what that means. "Plausible mechanism" is not the same as "proven benefit in people." The stronger claim you will see elsewhere, that citicoline is neuroprotective in humans, comes from preclinical work in cells and animals. That evidence has not been matched by results in large human trials. For a fuller background, see what citicoline is.

In the United States, citicoline is sold as a dietary supplement. It is not an FDA-approved drug, and no supplement sold in the US is approved to treat any disease.

The evidence, condition by condition, with the negative results first

The fairest way to summarize citicoline research is to start with the biggest and best trials, because those are the ones most likely to be true.

Acute stroke. The largest trial of citicoline ever run was ICTUS, published in The Lancet in 2012 by Dávalos and colleagues, with about 2,300 people. It found no improvement in 90-day recovery versus placebo. Earlier meta-analyses of smaller stroke trials had suggested benefit, but that suggestion was not confirmed by the largest trial. This pattern, small trials look promising, the big trial disappoints, is common in medicine, and it is why trial size and quality matter more than the number of positive headlines.

If you are reading this page because of symptoms right now: sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately. Do not take a supplement and wait.

Traumatic brain injury. The COBRIT trial, published in JAMA in 2012 by Zafonte and colleagues, tested citicoline after traumatic brain injury and found it did not improve functional or cognitive outcomes versus placebo. Again: a large, careful trial, and a negative result.

Chronic cerebrovascular cognitive decline. A Cochrane review by Fioravanti and Yanagi found modest short-term benefit on memory and behaviour in this setting. The honest caveats matter: the trials were short and of low quality, so this signal is weaker than it sounds. Relatedly, the IDEALE study (Cotroneo) in mild vascular cognitive impairment was observational, people taking citicoline had stable scores while an untreated group declined. Observational designs cannot prove the supplement caused the difference. The memory evidence page goes deeper, and the condition-by-condition evidence index covers the rest.

Glaucoma. Small trials from the Parisi and Rossetti groups found changes in electrophysiological measures when citicoline was used as an adjunct. Whether that translates into slowing actual vision loss is not established. See citicoline and glaucoma.

Attention in healthy people. McGlade and colleagues ran small trials in healthy adult women (2012, 250 mg and 500 mg doses) and in adolescent males, both funded by Cognizin's maker. Both found better scores on attention tests, and the adolescent trial also found gains in psychomotor speed. Industry funding does not make results false, but it is a reason to want independent replication before treating them as settled.

ADHD. There are no adequate trials of citicoline for ADHD. There is no good evidence that citicoline treats ADHD, and the ADHD evidence page says exactly that.

How the grading works

Rather than flatten all research into "studies show," this site assigns tiers:

• T1, large randomized trials and the most rigorous evidence. ICTUS and COBRIT sit here. Both were negative.
• T2, meta-analyses and systematic reviews, like the Cochrane review. Useful, but only as strong as the trials they pool.
• T3a, observational studies, like IDEALE. Suggestive, not proof.
• T3b, mechanistic and pharmacology evidence in humans, like the levodopa interaction.
• T4, preclinical and expert-opinion level evidence.

A T1 negative result outweighs a stack of T3 positive ones. That is the core logic of the site.

Safety and interactions: what is actually known

Across trials, citicoline has been generally well tolerated at doses from 250 mg to 2,000 mg per day. The side effects that show up are mostly mild: gastrointestinal upset, headache, and insomnia. The side effects page and the doses used in studies page cover this in more detail.

Two gaps deserve plain language. First, there is a lack of data in pregnancy and breastfeeding, so use in those situations is a conversation for your doctor, not a label claim. Second, citicoline may enhance the effects of levodopa. If you have Parkinson's disease and take levodopa, involve your neurologist before adding citicoline. The safety overview is the starting point for these questions, and the questions to ask your doctor page can help you structure that conversation.

If you and your doctor decide to try it

This site will not tell you to take citicoline. If you and your clinician decide a trial of it makes sense, the practical questions become: what dose ranges were used in studies, how the compound compares to alternatives such as alpha-GPC, and how to read a label so you know what you are actually buying. The comparison pages and the supplement-choosing guide handle those, and only those pages discuss specific products.

A note on how to read this site

Every efficacy claim here can be traced to a named study, and the grade next to it tells you how much weight to give it. When new, better evidence appears, especially large trials, the pages change. If you spot something that looks wrong or overstated, the contact page is open. The goal is a reference you can bring to an appointment and trust not to waste your doctor's time.